Markt geschlossen· · EUR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the Cancer Science Institute of Singapore London, United Kingdom, 29 September 2026 – 4BIO Capital,
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.
Giovanni Amabile, Founder and CEO Giovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the C
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.